ROCKVILLE, Md., April 4, 2005 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced the appointment of Ronald R. Baker to the position of vice president for sales and marketing, a newly created position reporting to the company's chief executive officer.
"The appointment of a vice president of sales and marketing highlights the importance we place upon establishing a strong sales infrastructure, as well as our optimism about the market potential for the company's AutoloGel(tm) therapy. Ron has extensive experience within the healthcare industry -- managing and implementing sales and marketing programs for both public and private organizations. His demonstrated success in exceeding goals, developing strategic partnerships and creating marketing opportunities were important considerations in his selection. These qualities will be invaluable to Cytomedix as the company evolves and we increase our sales efforts," said Dr. Kshitij Mohan, chief executive officer of Cytomedix.
Mohan emphasized that the position complements the recently announced appointment of KOL Bio-Medical Instruments, Inc. to represent the company in select east coast territories of the United States.
Baker currently serves as president of Bioventions, Inc., a consulting company he founded in early 2004 specializing in strategic planning, marketing and business development for emerging BioTech and Pharma companies. Prior, he served as vice president for sales, marketing, project management and regulatory services for BioReliance Corporation, based in Rockville, Maryland, which was acquired by Invitrogen (Nasdaq: IVGN) in February 2004.
His earlier experience includes serving as general manager and director of business development for Diagnostic Assay Services, based in Gaithersburg, Maryland; vice president, sales and marketing for Molecular Oncology, Gaithersburg, Maryland; vice president, corporate marketing for International Clinical Laboratories, Inc., Nashville, Tennessee; director of sales and marketing for the same organization in Syosset, New York; marketing manager, clinical testing division, Corning Healthcare (MetPath, Inc.), Teterboro, New Jersey; and various sales, marketing and technical positions for F. Hoffman-La Roche, Nutley, New Jersey.
Baker earned a Bachelor of Science degree in biology from Loyola College, Baltimore, Maryland, and did graduate work in Business Administration at Fairleigh Dickinson University, Rutherford, NJ. About Cytomedix
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for uses in the treatment of wounds and other applications. The current offering is the AutoloGel(tm) system, a technology that utilizes an autologous platelet gel composed of multiple growth factors and fibrin matrix. The company is conducting a well-controlled, blinded, prospective, multi-center clinical trial on the use of its technology in healing diabetic foot ulcers. Cytomedix is working with healthcare providers to offer an advanced therapy at the point-of-care in multiple settings. Additional information is available at: www.cytomedix.com.
Forward Looking Statements
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the success of new sales initiatives, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.